Aldeyra Therapeutics, Inc. (ALDX)Healthcare | Biotechnology | Lexington, United States | NasdaqCM
1.80 USD
After hours: 1.80 0.00 (0.000%) ⇩ (April 17, 2026, 7:57 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:16 a.m. EDT
Disappointing fundamentals met with aggressive call buying signals a 'dead cat' bounce or a forced credit play rather than organic momentum. Prices are trading 50% below their 50-day average with negative earnings, making it a high-risk trap unless there is a hidden catalyst. The $1.80 price is likely a resistance ceiling formed by short-term traders hitting targets, with no immediate margin of safety for long-term capital. Avoid for long-term hold; only for speculative momentum trades with tight stops. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.484163 |
| AutoTheta | 0.509794 |
| AutoETS | 0.530482 |
| MSTL | 0.536920 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 300.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.034 |
| Excess Kurtosis | -1.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 35.096 |
| Market Cap | 108,329,008 |
| Forward P/E | -6.99 |
| Beta | 1.33 |
| Website | https://www.aldeyra.com |
As of April 19, 2026, 12:16 a.m. EDT: Options flow shows a significant bullish bias. July-September expirations have massive equity flow into calls (especially the $10 strike with 280 volume, +455% spike), while put activity is subdued. Despite higher implied volatility (IV) for near-term calls, the positioning of speculators is heavily skewed toward upside protection or leveraged gains at higher strikes. The ATM IV for calls is relatively low compared to historical averages in other biotech contexts, suggesting smart money is paying up for upside exposure rather than waiting for a IV spike to sell.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.1964286 |
| Address1 | 131 Hartwell Avenue |
| Address2 | Suite 320 |
| All Time High | 16.7 |
| All Time Low | 1.07 |
| Ask | 2.31 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 1,754,140 |
| Average Daily Volume3 Month | 3,017,238 |
| Average Volume | 3,017,238 |
| Average Volume10Days | 1,754,140 |
| Beta | 1.329 |
| Bid | 1.32 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.736 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.8 |
| Current Ratio | 2.581 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.86 |
| Day Low | 1.79 |
| Debt To Equity | 35.096 |
| Display Name | Aldeyra Therapeutics |
| Earnings Timestamp End | 1,778,875,200 |
| Earnings Timestamp Start | 1,778,875,200 |
| Ebitda | -35,013,212 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.537 |
| Enterprise Value | 53,817,924 |
| Eps Current Year | -0.40333 |
| Eps Forward | -0.2575 |
| Eps Trailing Twelve Months | -0.56 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 339 674 6495 |
| Fifty Day Average | 3.5512 |
| Fifty Day Average Change | -1.7512 |
| Fifty Day Average Change Percent | -0.49312907 |
| Fifty Two Week Change Percent | -19.64286 |
| Fifty Two Week High | 6.175 |
| Fifty Two Week High Change | -4.375 |
| Fifty Two Week High Change Percent | -0.708502 |
| Fifty Two Week Low | 1.07 |
| Fifty Two Week Low Change | 0.7299999 |
| Fifty Two Week Low Change Percent | 0.6822429 |
| Fifty Two Week Range | 1.07 - 6.175 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,399,037,400,000 |
| Float Shares | 48,559,681 |
| Forward Eps | -0.2575 |
| Forward P E | -6.990291 |
| Free Cashflow | -21,461,964 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03201 |
| Held Percent Institutions | 0.65759003 |
| Implied Shares Outstanding | 60,182,783 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts. |
| Long Name | Aldeyra Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 108,329,008 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_47399863 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -33,846,660 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 108,930,835 |
| Number Of Analyst Opinions | 6 |
| Open | 1.85 |
| Operating Cashflow | -33,345,682 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 781 761 4904 |
| Post Market Change | -0.000099897385 |
| Post Market Change Percent | -0.005549855 |
| Post Market Price | 1.7999 |
| Post Market Time | 1,776,470,274 |
| Previous Close | 1.8 |
| Price Eps Current Year | -4.4628468 |
| Price Hint | 4 |
| Price To Book | 2.445652 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.519 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 1.86 |
| Regular Market Day Low | 1.79 |
| Regular Market Day Range | 1.79 - 1.86 |
| Regular Market Open | 1.85 |
| Regular Market Previous Close | 1.8 |
| Regular Market Price | 1.8 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,291,166 |
| Return On Assets | -0.24952 |
| Return On Equity | -0.58733004 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 60,182,782 |
| Shares Percent Shares Out | 0.0912 |
| Shares Short | 5,491,622 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,253,462 |
| Short Name | Aldeyra Therapeutics, Inc. |
| Short Percent Of Float | 0.094 |
| Short Ratio | 0.86 |
| Source Interval | 15 |
| State | MA |
| Symbol | ALDX |
| Target High Price | 13.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 7.5 |
| Target Median Price | 8.0 |
| Total Cash | 70,041,256 |
| Total Cash Per Share | 1.164 |
| Total Debt | 15,530,169 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.731075 |
| Two Hundred Day Average Change | -2.9310749 |
| Two Hundred Day Average Change Percent | -0.61953676 |
| Type Disp | Equity |
| Volume | 1,291,166 |
| Website | https://www.aldeyra.com |
| Zip | 2,421 |